Biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) stated on Wednesday its Non-GAAP net income of USD38.4m for the full year ended 31 December 2018.
This is a growth when compared with a Non-GAAP net loss of USD3.4m for the full year 2017.
Total revenues of USD193.118m were collected for the full year ended 31 December 2018, up from total revenues of USD165.08m for the full year 2017.
For the full year 2019, the company anticipates total revenues in the USD215m and USD225m range.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva